Intravacc has partnered with contract development and manufacturing organisation (CDMO) Celonic Group for the design, development and production of a Covid-19 vaccine.

The vaccine will be based on an immunogenic Spike (S) protein of SARS-CoV-2 and Intravacc’s Outer Membrane Vesicle (OMV) technology.

Intravacc’s OMV platform will be combined with S-proteins expressed by Celonic’s CHOvolution mammalian cell expression system. This combination is expected to induce an effective and balanced B and T cell response against SARS-CoV-2.

Celonic will create cell lines producing the S-protein in high quantities and develop a GMP production process. Pre-clinical studies will be performed to select a candidate protein for the vaccine.

Celonic Group CEO Dr Konstantin Matentzoglu said: “The novel vaccine has the potential to prevent morbidity and mortality of Covid-19. Together, we have an opportunity to make a difference in the lives of patients at this time of great need.”

Intravacc and Celonic intend to expedite development of the former’s Covid-19 OMV protein vaccine, which is expected to advance into clinical testing next year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Intravacc CEO Dr Jan Groen said: “Several studies have shown that OMVs have the ability to enhance the immune response and can be relatively easy formulated with target-specific peptides and proteins.

“This, combined with the fact they can be quickly scaled-up for manufacturing, makes it an ideally suited platform under the current circumstances where quantity and speed are critical.”

In March, Intravacc commenced activities to develop four Covid-19 vaccine candidate based on its Vero cell, OMV and iBoost technologies.

The company formed multiple alliances to develop potential vaccines against Covid-19, including collaborations with EpiVax, Wageningen Bioveterinary Research (WBVR) and Utrecht University.

Earlier this month, Intravacc collaborated with cancer immunotherapies developer CimCure to in-license the latter’s iBoost technology for vaccines.